NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_
On January 10, 2025, NextCure, Inc. (NASDAQ: NXTC) made a significant announcement through a press release, indicating the dosing of the first patient in the Phase 1 study of LNCB74. LNCB74 represents a B7-H4-targeting antibody-drug conjugate (ADC), strategically designed as a therapeutic approach for the treatment of multiple cancers. Dr. Udayan Guha, Senior Vice President […]
More Stories
YouGov (LON:YOU) Sets New 1-Year Low – Here’s What Happened
YouGov plc (LON:YOU – Get Free Report)’s stock price reached a new 52-week low on Friday . The stock traded...
Bunge Global (NYSE:BG) Shares Up 5.9% – Here’s Why
Bunge Global SA (NYSE:BG – Get Free Report) was up 5.9% during mid-day trading on Friday . The stock traded...
WD-40 (NASDAQ:WDFC) Releases FY25 Earnings Guidance
WD-40 (NASDAQ:WDFC – Get Free Report) issued an update on its FY25 earnings guidance on Friday morning. The company provided...
Johnson Matthey (LON:JMAT) Sets New 1-Year Low – Time to Sell?
Johnson Matthey PLC (LON:JMAT – Get Free Report) reached a new 52-week low during trading on Friday . The company...
WisdomTree India Earnings Fund (NYSEARCA:EPI) Sees Strong Trading Volume – Should You Buy?
Shares of WisdomTree India Earnings Fund (NYSEARCA:EPI – Get Free Report) saw strong trading volume on Friday . 1,959,819 shares...
Blue Bird (NASDAQ:BLBD) Trading Up 5.9% – Here’s Why
Blue Bird Co. (NASDAQ:BLBD – Get Free Report)’s share price was up 5.9% during trading on Friday . The stock...